» Articles » PMID: 38868744

Well-differentiated G1 and G2 Pancreatic Neuroendocrine Tumors: a Meta-analysis of Published Expanded DNA Sequencing Data

Overview
Specialty Endocrinology
Date 2024 Jun 13
PMID 38868744
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Well-differentiated pancreatic neuroendocrine tumors (PNETs) can be non-functional or functional, e.g. insulinoma and glucagonoma. The majority of PNETs are sporadic, but PNETs also occur in hereditary syndromes, primarily multiple endocrine neoplasia type 1 (MEN1). The Knudson hypothesis stated a second, somatic hit in as the cause of PNETs of MEN1 syndrome. In the recent years, reports on genetic somatic events in both sporadic and hereditary PNETs have emerged, providing a basis for a more detailed molecular understanding of the pathophysiology. In this systematic review and meta-analysis, we made a collation and statistical analysis of aggregated frequent genetic alterations and potential driver events in human grade G1/G2 PNETs.

Methods: A systematic search was performed in concordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) reporting guidelines of 2020. A search in Pubmed for published studies using whole exome, whole genome, or targeted gene panel (+400 genes) sequencing of human G1/G2 PNETs was conducted at the 25 of September 2023. Fourteen datasets from published studies were included with data on 221 patients and 225 G1/G2 PNETs, which were divided into sporadic tumors, and hereditary tumors with pre-disposing germline variants, and tumors with unknown germline status. Further, non-functioning and functioning PNETs were distinguished into two groups for pathway evaluation. The collated genetical analyses were conducted using the 'maftools' R-package.

Results: Sporadic PNETs accounted 72.0% (162/225), hereditary PNETs 13.3% (30/225), unknown germline status 14.7% (33/225). The most frequently altered gene was , with somatic variants and copy number variations in overall 42% (95/225); hereditary PNETs (germline variations in , , , , , , and/or ) 57% (16/30); sporadic PNETs 36% (58/162); unknown germline status 64% (21/33). The point mutations/indels were distributed throughout . Overall, (16%, 37/225) and -variants (12%, 27/225) were also abundant with missense mutations clustered in mutational hotspots associated with histone binding, and translocase activity, respectively. mutations occurred more frequently in PNETs with mutations, p<0.05. While functioning PNETs shared few variated genes, non-functioning PNETs had more recurrent variations in genes associated with the Phosphoinositide 3-kinase, Wnt, NOTCH, and Receptor Tyrosine Kinase-Ras signaling onco-pathways.

Discussion: The somatic genetic alterations in G1/G2 PNETs are diverse, but with distinct differences between sporadic vs. hereditary, and functional vs. non-functional PNETs. Increased understanding of the genetic alterations may lead to identification of more drivers and driver hotspots in the tumorigenesis in well-differentiated PNETs, potentially giving a basis for the identification of new drug targets. (Funded by Novo Nordisk Foundation, grant number NNF19OC0057915).

Citing Articles

Gastroenteropancreatic Neuroendocrine Tumors: Does Tumor Location Affect Prognosis?.

Ozsoy M, Erol C, Aydemir M, Baysal H, Buyuker F, Seneldir H Arch Iran Med. 2025; 28(1):29-39.

PMID: 40001327 PMC: 11862391. DOI: 10.34172/aim.33366.

References
1.
Aguilera P, Lopez-Contreras A . ATRX, a guardian of chromatin. Trends Genet. 2023; 39(6):505-519. DOI: 10.1016/j.tig.2023.02.009. View

2.
Bahar M, Kim H, Kim D . Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023; 8(1):455. PMC: 10725898. DOI: 10.1038/s41392-023-01705-z. View

3.
Ewing B, Green P . Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998; 8(3):186-94. View

4.
Guilmette J, Nose V . Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. Adv Anat Pathol. 2018; 26(1):13-30. DOI: 10.1097/PAP.0000000000000201. View

5.
Wu G, Yuan M, Shen S, Ma X, Fang J, Zhu L . Menin enhances c-Myc-mediated transcription to promote cancer progression. Nat Commun. 2017; 8:15278. PMC: 5424160. DOI: 10.1038/ncomms15278. View